Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Mabworks Biotech Co. Ltd.
DescriptionVariant of Zmapp, a combination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationEbola
Indication DetailsTreat Ebola virus infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today